1 study found for:    mk-2206 endometrial
Show Display Options
Rank Status Study
1 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Carcinoma;   Endometrial Clear Cell Adenocarcinoma;   Endometrial Serous Adenocarcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Akt Inhibitor MK2206;   Other: Laboratory Biomarker Analysis

Indicates status has not been verified in more than two years